U.S. markets open in 8 hours 57 minutes
  • S&P Futures

    4,402.00
    +7.25 (+0.16%)
     
  • Dow Futures

    34,743.00
    +53.00 (+0.15%)
     
  • Nasdaq Futures

    15,090.75
    +17.25 (+0.11%)
     
  • Russell 2000 Futures

    2,198.40
    +6.70 (+0.31%)
     
  • Crude Oil

    68.41
    +0.26 (+0.38%)
     
  • Gold

    1,814.00
    -0.50 (-0.03%)
     
  • Silver

    25.44
    -0.02 (-0.06%)
     
  • EUR/USD

    1.1840
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.1840
    -1.1760 (-100.00%)
     
  • Vix

    17.97
    -18.04 (-100.00%)
     
  • GBP/USD

    1.3893
    +0.0008 (+0.06%)
     
  • USD/JPY

    109.6870
    +0.2190 (+0.20%)
     
  • BTC-USD

    39,406.31
    +1,568.53 (+4.15%)
     
  • CMC Crypto 200

    973.03
    +46.27 (+4.99%)
     
  • FTSE 100

    7,123.86
    +18.14 (+0.26%)
     
  • Nikkei 225

    27,712.87
    +128.79 (+0.47%)
     

How Many Molecular Templates, Inc. (NASDAQ:MTEM) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls Molecular Templates, Inc. (NASDAQ:MTEM), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that have been privatized tend to have low insider ownership.

Molecular Templates is a smaller company with a market capitalization of US$621m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Molecular Templates.

See our latest analysis for Molecular Templates

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Molecular Templates?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Molecular Templates does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Molecular Templates' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Molecular Templates. Our data shows that Santé Ventures, LLC is the largest shareholder with 15% of shares outstanding. In comparison, the second and third largest shareholders hold about 7.0% and 6.4% of the stock.

On further inspection, we found that more than half the company's shares are owned by the top 8 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Molecular Templates

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own less than 1% of Molecular Templates, Inc.. It seems the board members have no more than US$4.3m worth of shares in the US$621m company. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling.

General Public Ownership

With a 20% ownership, the general public have some degree of sway over Molecular Templates. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With an ownership of 21%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Public Company Ownership

It appears to us that public companies own 5.9% of Molecular Templates. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Molecular Templates you should know about.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.